For the purpose of understanding How cancer outwit the immune system, we could imagine the situation as a police-robber chase. In 2004, Robert Schreiber, an immunologist and professor of Pathology and Immunology at the University of Washington, proposed a theory of how this happens. Schreiber called this process “cancer immunoediting” and divided it into three stages: Elimination, Equilibrium, and Escape.
They discover a new turning point under the Antarctic ice
The three “es” of cancer cells
The immune system, like invisible army that continually patrols our body looking for intruders, has the ability to recognize a high percentage of cancer cells as foreign and eliminate them. This is the process known as the Immune Elimination phase. It seems that our immune system is very good at this stage, or at least at the beginning.
However, some cancer cells manage to survive evading the internal police. They do not grow uncontrollably, but they are not eliminated either. They are in a state of waiting, accumulating small changes that will help them later. It is the Balance phase. Thus, there appears to be a latency period between the end of the Elimination phase and the beginning of the Escape phase.
Finally, in the Escape phase tumor cells have modified their ability to be recognized by the immune system learning to disguise and camouflage themselves. They develop tricks to evade detection, which allows them to grow and multiply undisturbed.
They cleverly learn to send out the same “peace signals” that healthy cells generate so that the immune system does not attack them by mistake. These peace signals are known as immune checkpoints, and their function is to put the army that defends us to sleep when we are in a safe situation. Thus, finally, the tumor cells go unnoticed by the immune system and the tumor manages to grow. and increase its aggressiveness. So, what seemed to be an effective immune system against cancer turns out to be deceived by the tumor itself, which manipulates it to its advantage in order to spread rapidly throughout our body.
In short, cancer is not only a disease of uncontrolled cells, but also a constant battle between those cells and our immune system where, sometimes, cancer manages to take advantage.
But the story doesn’t end there. While the tumor struts around in its costume and celebrates its supposed victory, a new player appears on the scene: immunotherapy.
Can a mushroom cure cancer? It’s not that simple
A new weapon of the invisible army
Immunotherapy is a therapeutic technique that harnesses the immune system’s powerful weapons to identify and destroy cancer cells, even those hiding behind clever disguises. It helps the immune system recognize that the disguise they are wearing is nothing more than a ruse, and that Its true nature poses a threat that must be eliminated.
Before the 21st century, the main treatments for cancer were surgery, radiotherapy and chemotherapy. But there was a telling moment more than a century ago when scientists noticed something peculiar. They discovered that Some advanced cancers disappeared completely after the affected people suffered severe bacterial infections. and, consequently, a great activation of the immune system. This raised the question: can the immune system fight cancer?
Immunotherapy was born in response to this question and completely revolutionized the way we treat cancer. Instead of targeting just cancer cells, scientists realized that they had to consider the entire environment in which tumors grow, what we call the “tumor microenvironment”. In this microenvironment, not only cancer cells coexist, but also a very large repertoire of different cells, among which are those of the immune system.
Unlike traditional chemotherapy, which primarily aims to eliminate rapidly dividing cells, immunotherapy focuses on help the immune system to recognize cancer as something foreign and eliminate it in a way that prevents tumor growth and spread.
Goodbye to mammography? This radiation-free tool may improve breast cancer detection
“It is here to stay”
“Many mistakes were made in cancer research, we didn’t know enough about the immune system. (…) Immunotherapy is here to stay and will be able to combat many types of cancer.” This is how immunologist James Allison expressed his certainty after receiving the Nobel Prize in Medicine in 2018 together with immunologist Tasuku Honjo.
Immunotherapy treatments are much more specific than other therapeutic alternatives such as the aforementioned chemotherapy, which carries less severe side effects. Furthermore, by boosting the immune system’s memory it allows it to continue recognizing the tumor as “foreign”, thus prolonging its action and offering potential long-term benefits.
And unlike traditional methods, such as radiotherapy or chemotherapy, which are often not curative, immunotherapy offers a different perspective. Once the immune system generates soldiers that go out and kill the cancer cells, we have them for the rest of our lives. This leads to long survivals for some patients who receive this type of treatment.
However, one might wonder why immunotherapy is not a treatment for all cancer patients.
Cold and hot tumors
Cancer is a group of diverse diseases and, as such, each tumor has its own behavior. Our immune cells are our main allies in the treatment of cancer immunotherapy. In some cases, more than 40% of the tumor may be made up of these defensive cells. It is what is known as a “hot tumor” and seems to respond better to this type of treatment.
On the other hand, there are tumors with few infiltrated immune cells, like glioblastoma. Known as “cold tumors”, immunotherapy is not as efficient in them. However, strategies are being studied to increase the number of infiltrating defense cells in these tumors and thus improve the effectiveness of treatment.
In addition, specific characteristics of cancer patients that may be predictive are being investigated. identify which ones will benefit most from immunotherapy.
“Of course, while there may not be any truly curative treatments, there are many therapies that can prolong life, with quality of life, until such new cures appear. There is a lot of science under development and progress is being made rapidly. I would say it is time for optimism. But we have a long way to go, which also requires hard work and needs the support of the public to achieve it,” James Allison confided in another interview.
This article was the winner of the 4th edition of the youth outreach competition organised by the Lilly Foundation and The Conversation Spain.
Candelaria Aguilar García, Predoctoral Researcher in Tumor Immunology (ISPA), Oviedo University
This article was originally published on The Conversation. Read the original.